Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, 1830 E. Monument St, Room 555, Baltimore, MD, 21287, USA.
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
Respir Res. 2022 Aug 1;23(1):198. doi: 10.1186/s12931-022-02115-5.
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) for children aged < 1 year in March 2015. Previous vaccine effectiveness (VE) studies for pneumonia have used invasive pneumococcal disease or chest X-rays. None have used ultrasound. We sought to determine the VE of PCV10 against sonographically-confirmed pneumonia in three subdistrict health complexes in Bangladesh.
We conducted a matched case-control study between July 2015 and September 2017 in three subdistricts of Sylhet, Bangladesh. Cases were vaccine-eligible children aged 3-35 months with sonographically-confirmed pneumonia, who were matched with two types of controls by age, sex, week of diagnosis, subdistrict health complex (clinic controls) or distance from subdistrict health complex (community controls) and had an illness unlikely due to Streptococcus pneumoniae (clinic controls) or were healthy (community controls). VE was measured using multivariable conditional logistic regression.
We evaluated 8926 children (average age 13.3 months, 58% boys) with clinical pneumonia by ultrasound; 2470 had pneumonia with consolidations ≥ 1 cm; 1893 pneumonia cases were matched with 4238 clinic controls; and 1832 were matched with 3636 community controls. VE increased with the threshold used for consolidation size on ultrasound: the adjusted VE of ≥ 2 doses vs. non-recipients of PCV10 against pneumonia increased from 15.8% (95% CI 1.6-28.0%) for consolidations ≥ 1 cm to 29.6% (12.8-43.2%) for consolidations ≥ 1.5 cm using clinic controls and from 2.7% (- 14.2-17.2%) to 23.5% (4.4-38.8%) using community controls, respectively.
PCV10 was effective at reducing sonographically-confirmed pneumonia in children aged 3-35 months of age when compared to unvaccinated children. VE increased with the threshold used for consolidation size on ultrasound in clinic and community controls alike. This study provides evidence that lung ultrasound is a useful alternative to chest X-ray for case-control studies evaluating the effectiveness of vaccines against pneumonia.
孟加拉国于 2015 年 3 月为年龄小于 1 岁的儿童引入了 10 价肺炎球菌结合疫苗(PCV10)。以前针对肺炎的疫苗效力(VE)研究使用了侵袭性肺炎球菌病或胸部 X 光。但都没有使用超声。我们旨在确定孟加拉国三个分区卫生综合体中 PCV10 对超声确诊肺炎的 VE。
我们于 2015 年 7 月至 2017 年 9 月在孟加拉国锡尔赫特的三个分区进行了病例对照研究。病例为符合条件的 3-35 月龄儿童,超声检查证实患有肺炎,按照年龄、性别、诊断周、分区卫生综合体(诊所对照)或与分区卫生综合体的距离(社区对照)与两种类型的对照匹配,且疾病不太可能由肺炎链球菌引起(诊所对照)或身体健康(社区对照)。使用多变量条件逻辑回归测量 VE。
我们通过超声评估了 8926 名患有临床肺炎的儿童(平均年龄 13.3 个月,58%为男孩);2470 名患有肺炎且有 1cm 以上实变;1893 名肺炎病例与 4238 名诊所对照相匹配;1832 名与 3636 名社区对照相匹配。随着超声检查中实变大小阈值的使用,调整后的 VE 也随之增加:≥2 剂 PCV10 对肺炎的调整 VE 从 1cm 以上实变的 15.8%(95%CI 1.6-28.0%)增加到诊所对照中 1.5cm 以上实变的 29.6%(12.8-43.2%),而社区对照中从 2.7%(-14.2-17.2%)增加到 23.5%(4.4-38.8%)。
与未接种疫苗的儿童相比,PCV10 对 3-35 月龄儿童的超声确诊肺炎具有有效性。VE 随着超声检查中实变大小阈值的使用而增加,无论是在诊所对照还是社区对照中都是如此。本研究提供了证据,表明肺部超声是一种替代胸部 X 光的有用方法,可用于评估疫苗对肺炎的有效性的病例对照研究。